Page results
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
A study of patients at UCLH and North Middlesex University Hospital published in The Lancet Infectious Diseases suggests that the B.1.17. variant of Covid-19 is not associated with more severe illness and death, but appears to lead to higher virus load.
-
The Integrated Children and Adolescent Service is a long-established outpatient service of the Royal London Hospital for Integrated Medicine at UCLH.
-
UCLH-led research paper outlines mechanism behind rare cases of blood clots and low platelets after vaccination
-
UCLH is to lead an initiative to improve care for myeloma patients alongside Oxford University Hospitals NHS Foundation Trust (OUH) and University Hospital Southampton NHS Foundation Trust (UHS).
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Prime Minister Boris Johnson visited the vaccination centre at the Islington Business Design Centre yesterday.
-
A BBC One documentary featuring clinicians at UCLH which airs this Thursday highlights the harm to the body and brain caused by ultra-processed food.
-
UCLH and UCL neurologists have published the first clinical observations of patients who experienced an ischaemic stroke, the most common form of stroke, following an Oxford AstraZeneca vaccine.
File results
-
FOI/2023/0034 - Trusts video consultation solutions
-
FOI/2023/0025 - Surgical operating tables used in Trust
-
FOI/2023/0037 - Assault attendances to Emergency Department
-
FOI/2023/0038 - Cases where breast milk of a new mother was given to a child who is not her own
-
FOI/2023/0063 - Women who have given birth at the Trust aged 50 or above
-
FOI/2023/0065 - A&E deaths from 2010 to 2022
-
FOI/2023/0064 - Children's operations cancelled/ delayed for non-clinical reasons from 2018 to 2022
-
FOI/2022/0794 - Communication personnel and communication spend
-
FOI/2023/0058 - Skin cancer pathway management
-
FOI/2023/0054 - Local formulary used at the Trust